NeoGenomics (NASDAQ:NEO) Issues Earnings Results

NeoGenomics (NASDAQ:NEO) issued its quarterly earnings results on Tuesday. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05), Zacks reports. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%.

NeoGenomics Trading Up 3.7 %

NASDAQ NEO opened at $14.42 on Tuesday. NeoGenomics has a twelve month low of $12.13 and a twelve month high of $19.11. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.99 and a quick ratio of 1.91. The company’s 50-day simple moving average is $15.70 and its 200 day simple moving average is $15.59.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NEO. The Goldman Sachs Group decreased their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Benchmark lowered NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Jefferies Financial Group started coverage on NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a report on Friday, January 10th. Finally, Bank of America boosted their price objective on shares of NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $20.20.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.